I believe we as shareholders feel so neglected by GC and starving for info on what exactly has transpired these past 18 months. Proxy problems, no uplisting, missed milestones, etc. Its not that we would be unreasonable as we know it's a startup biotech on the OTC, it's just he did so well at communication with Blogs etc. Now we basically get nothing. I don't believe a "Tweet" once in awhile is treating us very respectfully. We can handle the truth.
(3)
(0)
Amarantus Bioscience Holdings (AMBS) Stock Research Links